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L I T E R A T U R E  H I G H L I G H T S
NEUROLOGY
Selected abstracts and commentary
Background: Over the past few decades, the burden of stroke
in developing countries has grown to epidemic proportions.
Two-thirds of global stroke occurs in low- and middle-income
countries. We have found that little information is obtainable
concerning the availabil ity of thrombolys is  therapy in
developing countries. Summary of review: The epidemiology of
stroke is well investigated in the developed world; however, in
the developing world stroke is less well documented. Most of
the available stroke data from these countries are hospital-
based. Stroke thrombolysis is currently used in few developing
countries like Brazil, Argentina, Senegal, Iran, Pakistan, China,
Thailand, and India. The two main barriers for implementation
of thrombolysis therapy in developing countries are the high
cost of tissue plasminogen activator and lack of proper
infrastructure. Most of the centers with the infrastructure to
deliver thrombolysis for stroke are predominantly private
sector, and only available in urban areas. Conclusion: Until a
more cost-effective thrombolytic agent and the proper
infrastructure for widespread use of thrombolysis therapy are
available, developing nations should focus on primary and
secondary stroke prevention strategies and the establishment
of stroke units wherever possible.  Such multi-faceted
approaches will be more cost-effective for developing countries
than the use of thrombolysis.
Pandian JD, Padma V, Vijaya P, Sylaja PN, Murthy JMK
Department of Neurology, Royal Brisbane and Women's Hospital, Brisbane, Australia; and Department of Neurology, All India Institute of Medical Sciences, New Delhi, India.
jeyarajpandian@yahoo.co.in
International Journal of Stroke 2007 Feb; 2:17-26.
STROKE THROMBOLYSIS IN DEVELOPING COUNTRIES
COMMENTARY
The paper by Pandian et al is a review article related to stroke in developing countries. The literature related to this topic is limited
despite a huge burden of stroke in the developing world. Factors responsible for the extremely low use of thrombolytics in these
countries are discussed. The article not only provides insight and analysis of the situation but makes recommendations. This
article is useful for clinicians and scientists involved in stroke research.
The EXCITE study is the first randomized, multi-center trial evaluating the role of constraint therapy in stroke rehabilitation. Upper
extremity functional limitation is present in 50-70% stroke survivors and is frustrating for occupational as well as physical
therapists. That constraining the normal hand leading to forced utilization of the hemiparetic or hemiplegic hand results in
significant recovery is a promising finding. The article also discusses cortical activation and other mechanisms underlying this
recovery.
The study by Kupsch and colleagues is promising. Primary generalized and segmental dystonia is a debilitating condition usually
refractory to medical therapy and poorly responsive to botox therapy. This is the first study reporting up to 50% improvement in
these patients by deep brain stimulation of the globus pallidus interna (GPi) as compared to sham stimulation. The treatment was
associated with adverse events over the 9-month study period. Long-term effects and adverse events are not known. Despite the
cost and the side effects, the findings are promising and provide hope for these otherwise incapacitated patients.    
Mohammad Wasay
Associate Professor of Neurology
Aga Khan University
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CONTEXT: Single-site studies suggest that a 2-week program of
constraint-induced movement therapy (CIMT) for patients more
than 1 year after stroke who maintain some hand and wrist
movement can improve upper extremity function that persists
for at least 1 year. OBJECTIVE: To compare the effects of a 2-
week multisite program of CIMT vs usual and customary care
on improvement in upper extremity function among patients
who had a first stroke within the previous 3 to 9 months.
DESIGN AND SETTING: The Extremity Constraint Induced
Therapy Evaluation (EXCITE) trial, a prospective, single-blind,
randomized, multisite clinical trial conducted at 7 US academic
institutions between January 2001 and January 2003.
PARTICIPANTS: Two hundred twenty-two individuals with
predominantly ischemic stroke. INTERVENTIONS: Participants
were assigned to receive either CIMT (n = 106; wearing a
restraining mitt on the less-affected hand while engaging in
repetitive task practice and behavioral shaping with the
hemiplegic hand) or usual and customary care (n = 116;
ranging from no treatment after  conc lud ing formal
rehabil i ta tion to  pharmacologic or phys iotherapeutic
interventions); patients were stratified by sex, prestroke
dominant side, side of stroke, and level of paretic arm
function. MAIN OUTCOME MEASURES: The Wolf Motor
Function Test (WMFT), a measure of laboratory time and
strength-based ability and quality of movement (functional
ability), and the Motor Activity Log (MAL), a measure of how
well and how often 30 common daily activities are performed.
RESULTS: From baseline to 12 months, the CIMT group
showed greater improvements than the control group in both
the WMFT Performance Time (decrease in mean time from
19.3 seconds to 9.3 seconds [52% reduction] vs from 24.0
seconds to 17.7 seconds [26% reduction]; between-group
difference, 34% [95% confidence interval {CI}, 12%-51%];
P<.001) and in the MAL Amount of Use (on a 0-5 scale,
increase from 1.21 to 2.13 vs from 1.15 to 1.65; between-
group difference, 0.43 [95% CI, 0.05-0.80]; P<.001) and
MAL Quality of Movement (on a 0-5 scale, increase from 1.26
to 2.23 vs 1.18 to 1.66; between-group difference, 0.48
[95% CI, 0.13-0.84]; P<.001). The CIMT group achieved a
decrease of 19.5 in self-perceived hand function difficulty
(Stroke Impact Scale hand domain) vs a decrease of 10.1 for
the control group (between-group difference, 9.42 [95% CI,
0.27-18.57]; P=.05). CONCLUSION: Among patients who had
a stroke within the previous 3 to 9 months, CIMT produced
statistically significant and clinically relevant improvements in
arm motor function that persisted for at least 1 year.Trial
Registration clinicaltrials.gov Identifier: NCT00057018.
BACKGROUND: Neurostimulation of the internal globus pallidus
has been shown to be effective in reducing symptoms of
primary dystonia. We compared this surgical treatment with
sham stimulation in a randomized, controlled clinical trial.
METHODS: For ty pat ients with  pr imary  segmental  or
generalized dystonia received an implanted device for deep-
brain stimulation and were randomly assigned to receive either
neurostimulation or sham stimulation for 3 months. The
primary end point was the change from baseline to 3 months
in the severity of symptoms, according to the movement
subscore on the Burke-Fahn-Marsden Dystonia Rating Scale
(range, 0 to 120, with higher scores indicating greater
impairment). Two investigators who were unaware of treatment
status assessed the severity of dystonia by reviewing
videotaped sessions. Subsequently, all patients received open-
label neurostimulation; blinded assessment was repeated after
6 months of active treatment. RESULTS: Three months after
randomization, the change from baseline in the mean (+/-SD)
movement  score was s ignif icantly  grea ter in the
neurostimulation group (-15.8+/-14.1 points) than in the
sham-stimulation group (-1.4+/-3.8 points, P<0.001). During
the open-label extension period, this improvement was
susta ined among patients  origina lly  assigned to the
neurostimulation group, and patients in the sham-stimulation
group had a similar benefit when they switched to active
treatment. The combined analysis of the entire cohort after 6
months of neurostimulation revealed substantial improvement
in all movement symptoms (except speech and swallowing),
Wolf SL et al, for the EXCITE investigators
Center for Rehabilitation Medicine, Emory University, Atlanta, USA. swolf@emory.edu
Journal of the American Medical Association 2006 Nov; 296:2095-2104.
EFFECT OF CONSTRAINT-INDUCED MOVEMENT THERAPY ON UPPER EXTREMITY FUNCTION
3 TO 9 MONTHS AFTER STROKE: THE EXCITE RANDOMIZED CLINICAL TRIAL
Kupsch A et al, for the Deep Brain Stimulation for Dystonia Study Group
Charite Universitatsmedizin, Campus Virchow, Berlin, Germany. j.volkmann@neurologie.uni-kiel.de
New England Journal of Medicine 2006 Nov; 355:1978-1990.
PALLIDAL DEEP-BRAIN STIMULATION IN PRIMARY GENERALIZED OR SEGMENTAL DYSTONIA
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the level of disability, and quality of life, as compared with
baseline scores. A total of 22 adverse events occurred in 19
patients, including 4 infections at the stimulator site and 1
lead dislodgment. The most frequent adverse event was
dysarthria. CONCLUSIONS: Bilateral pallidal neurostimulation
for 3 months was more effective than sham stimulation in
patients with primary generalized or segmental dystonia.
(ClinicalTrials.gov number, NCT00142259 [ClinicalTrials.gov].)
